Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib plus Docetaxel in Advanced Non-squamous NSCLC
NCT02364362Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of famitinib in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Primary endpoint: Maximum Tolerated Dose at 3 weeks. Started Jan 2015; status: completed.
02
Drugs
famitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02364362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02364362.